Shares of Sage Therapeutics, trading under NASDAQ:SAGE, experienced an 18% decline in after-hours trading following the release of its third-quarter earnings report. The company announced that it has halted further development of its drug zuranolone, intended for the treatment of major depressive disorder. Sage’s third-quarter earnings were generally consistent with expectations.
Sage Stock Drops 18% After Business Update and Earnings Report
Latest articles
roof cleaning
How a Dirty Roof Could Be Hurting Your Home’s Value
Your roof does more than just protect your home—it plays a crucial role in...
Gutter Cleaning
What’s The Best Way To Clean My Gutters In Cold Weather?
Gutters play a crucial role in protecting your home from water damage, especially in...
House Washing
What Is The Connection Between Clean Exteriors and Healthier Indoor Air
Did you know that the cleanliness of your home’s exterior can directly impact the...
Moving Services
What to Do While Movers Are Moving?
Moving day often feels chaotic, but with thoughtful preparation, you can transform it into...
More like this
roof cleaning
How a Dirty Roof Could Be Hurting Your Home’s Value
Your roof does more than just protect your home—it plays a crucial role in...
Gutter Cleaning
What’s The Best Way To Clean My Gutters In Cold Weather?
Gutters play a crucial role in protecting your home from water damage, especially in...
House Washing
What Is The Connection Between Clean Exteriors and Healthier Indoor Air
Did you know that the cleanliness of your home’s exterior can directly impact the...